CA 19-9 is NOT typically elevated in neuroendocrine tumours and should not be used as a screening or diagnostic marker for NETs.
CA 19-9 elevation in neuroendocrine tumours is uncommon (occurring in only 18.9% of cases), and when present, it generally indicates poor prognosis rather than serving as a useful diagnostic tool 1.
Key Evidence from Guidelines
The available guidelines specifically address CA 19-9 in the context of pancreatic adenocarcinoma, cholangiocarcinoma, and other gastrointestinal adenocarcinomas—not neuroendocrine tumours 2. The ASCO 2006 guidelines explicitly state that CA 19-9 is "elevated in many other tumors of the upper gastrointestinal tract, in ovarian cancer, hepatocellular cancer, and in colorectal cancer" but do not list neuroendocrine tumours as a condition where CA 19-9 is characteristically elevated 2.
The 2020 ESMO guidelines for gastroenteropancreatic neuroendocrine neoplasms 3 and the 2012 UK NET guidelines 4 make no mention of CA 19-9 as a relevant biomarker for NETs. Instead, these guidelines emphasize:
- Chromogranin A (CgA) as the primary general marker for NETs
- Specific peptide hormones for functioning tumours (gastrin, insulin, glucagon, VIP, somatostatin)
- Urinary 5-HIAA for serotonin-secreting tumours
- Neurokinin A for midgut NETs
Research Evidence on CA 19-9 and NETs
The research evidence confirms that CA 19-9 elevation in NETs is rare and clinically atypical:
Frequency of Elevation
- Only 18.9% of neuroendocrine tumours showed elevated CA 19-9 in a large retrospective study, compared to 81.5% of pancreatic adenocarcinomas 1
- In a Chinese study of gastroenteropancreatic NETs, only 12.4% had elevated CA 19-9 5
Clinical Significance When Elevated
When CA 19-9 is elevated in NETs, it appears to be a marker of aggressive disease:
- Elevated CA 19-9 in pancreatic NETs correlates with advanced TNM stage (III or IV) and serves as an adverse prognostic factor 6
- In GEP-NETs, elevated CA 19-9 is associated with G3 disease and distant metastasis, with median survival of only 10 months 5
- A case report documented CA 19-9-producing thymic NET as an extremely rare phenomenon, with CA 19-9 levels tracking disease progression 7
Clinical Implications
What This Means for Practice
Do not order CA 19-9 to diagnose or screen for NETs—it lacks sensitivity and specificity for this purpose
If CA 19-9 is incidentally elevated in a patient with a known NET, consider:
- This may indicate more aggressive tumor biology (G3 disease)
- Evaluate for metastatic disease, particularly liver metastases
- Recognize this as a poor prognostic indicator
If CA 19-9 is elevated and you're considering NET vs. adenocarcinoma:
- CA 19-9 elevation strongly favors pancreatic adenocarcinoma or cholangiocarcinoma over NET
- The vast majority of NETs will have normal CA 19-9
- Focus on appropriate NET markers: CgA, specific peptide hormones, and urinary 5-HIAA
Important Caveats
- Lewis antigen-negative patients (5% of population) cannot produce CA 19-9, making the test useless in this subset 2
- CA 19-9 can be elevated in benign biliary obstruction, pancreatitis, and renal failure, limiting specificity 2
- The rare NET that produces CA 19-9 represents an atypical presentation requiring heightened clinical suspicion for aggressive disease 7, 6